Quick Answer
Nautilus Biotechnology, Inc. reported Diluted EPS of $0.47 per share (loss) for fiscal year 2025.
Nautilus Biotechnology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.47 | +16.1% |
| 2024 | -$0.56 | -9.8% |
| 2023 | -$0.51 | -10.9% |
| 2022 | -$0.46 | +23.3% |
| 2021 | -$0.60 | -11.1% |
| 2020 | -$0.54 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.11 | +15.4% | +8.3% |
| June 30, 2025 | -$0.12 | +14.3% | +7.7% |
| March 31, 2025 | -$0.13 | +13.3% | +0.0% |
| September 30, 2024 | -$0.13 | +0.0% | +7.1% |
| June 30, 2024 | -$0.14 | -7.7% | +6.7% |
| March 31, 2024 | -$0.15 | -25.0% | -15.4% |
| September 30, 2023 | -$0.13 | -18.2% | +0.0% |
| June 30, 2023 | -$0.13 | -8.3% | -8.3% |
- Nautilus Biotechnology, Inc. showed an increase of +16.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Nautilus Biotechnology, Inc.’s diluted eps has grown by 13.0% (from $0.54 per share (loss) to $0.47 per share (loss)).
- The most recent figure is from Nautilus Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: